| Stereochemistry | ACHIRAL |
| Molecular Formula | C30H26F2N4O5 |
| Molecular Weight | 560.548 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
![Structure of N-[4-(6,7-dimethoxyquinolin-4-yl)oxy-3-fluorophenyl]-4-ethoxy-1-(4-fluoro-2-methylphenyl)pyrazole-3-carboxamide](/img/0bef631d-2e10-46c4-9290-ac2644fea6c1.svg?size=400&version=6&stereo=false "Structure of N-[4-(6,7-dimethoxyquinolin-4-yl)oxy-3-fluorophenyl]-4-ethoxy-1-(4-fluoro-2-methylphenyl)pyrazole-3-carboxamide")
SMILES
CCOC1=CN(N=C1C(=O)NC2=CC=C(OC3=C4C=C(OC)C(OC)=CC4=NC=C3)C(F)=C2)C5=CC=C(F)C=C5C
InChI
InChIKey=ISPBCAXOSOLFME-UHFFFAOYSA-N
InChI=1S/C30H26F2N4O5/c1-5-40-28-16-36(23-8-6-18(31)12-17(23)2)35-29(28)30(37)34-19-7-9-25(21(32)13-19)41-24-10-11-33-22-15-27(39-4)26(38-3)14-20(22)24/h6-16H,5H2,1-4H3,(H,34,37)
| Molecular Formula | C30H26F2N4O5 |
| Molecular Weight | 560.548 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
LDC1267 preferentially inhibits TAM tyrosine kinase receptors Tyro3, Axl and Mer at low nanomolarity. LDC1267 conferred therapeutic potential, efficiently enhancing anti-metastatic natural killer (NK) cells activity. In vivo the compound markedly reduced murine mammary cancer and melanoma metastases dependent on NK cells.
Originator
Approval Year
PubMed
Patents
Sample Use Guides
Mice treated intraperitoneally with LDC1267 (20 mg/kg) or by oral gavage LDC1267 (100 mg/kg).
Route of Administration:
Other
